SecBot SecBot
PRESS-RELEASE ·Filed Apr 15, 2026

PDSB

PDS Biotechnology Corporation
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Traders should monitor for upcoming full data readouts and potential partnerships or trial expansions; the current market cap of $59M may not reflect the potential value of these results if confirmed in larger trials.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.36
T+0 close · Apr 15, 2026 · via day close
Latest settled
−43.10%
T+60 · $0.7739
Vs SPY
−51.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $1.36entry
  2. T+1 · 7mo ago −5.88%α −6.14% · $1.28
  3. T+5 · 7mo ago −5.15%α −6.79% · $1.29
  4. T+20 · 6mo ago −19.12%α −25.16% · $1.10
  5. T+60 · 4mo ago −43.10%α −51.23% · $0.7739
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective response rate and over 80% two-year survival rate, compared to 35% and ~35% respectively in a parallel trial without PDS01ADC. These results suggest a potentially significant clinical improvement for the company's cancer therapy platform.

Key Facts

  • PDS01ADC trial showed 78% objective response rate vs 35% in control arm
  • Two-year survival rate exceeded 80% with PDS01ADC vs ~35% without
  • Data appears to demonstrate strong efficacy signal for PDSB's ADC platform

Financial Impact

Potential revaluation of PDSB's platform given strong survival and response rates in early data

marketCapenterpriseValuerevenue

Risk Factors

  • Data is preliminary and from a non-randomized parallel trial, raising potential selection bias
  • Small sample sizes could skew response and survival rates
  • Lack of regulatory approval path details or timeline

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274455

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026